Monoclonal Antibodies to SARS-associated Coronavirus (SARS-CoV): Identification of Neutralizing and Antibodies Reactive to S, N, M and E Viral Proteins

Overview

Journal J Virol Methods

Specialty Microbiology

Date 2005 May 12

PMID 15885812

Citations 47

Authors

Ralph A Tripp

Lia M Haynes

Deborah Moore

Barbara Anderson

Azaibi Tamin

Brian H Harcourt

Les P Jones

Mamadi Yilla

Gregory J Babcock

Thomas Greenough

Donna M Ambrosino

Rene Alvarez

Justin Callaway

Sheana Cavitt

Kurt Kamrud

Harold Alterson

Jonathan Smith

Jennifer L Harcourt

Congrong Miao

Raj Razdan

James A Comer

Pierre E Rollin

Thomas G Ksiazek

Anthony Sanchez

Paul A Rota

William J Bellini

Larry J Anderson

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (Mabs) against the Urbani strain of the SARS-associated coronavirus (SARS-CoV) were developed and characterized for reactivity to SARS-CoV and SARS-CoV S, N, M, and E proteins using enzyme-linked immunoabsorbent (ELISA), radioimmunoprecipitation, immunofluorescence, Western Blot and microneutralization assays. Twenty-six mAbs were reactive to SARS-CoV by ELISA, and nine were chosen for detailed characterization. Five mAbs reacted against the S protein, two against the M protein, and one each against the N and E proteins. Two of five S protein mAbs neutralized SARS-CoV infection of Vero E6 cells and reacted to an epitope within amino acids 490-510 in the S protein. While two of the three non-neutralizing antibodies recognized at second epitope within amino acids 270-350. The mAbs characterized should prove useful for developing SARS-CoV diagnostic assays and for studying the biology of infection and pathogenesis of disease.

Citing Articles

Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.

Sankhala R, Dussupt V, Chen W, Bai H, Martinez E, Jensen J Structure. 2023; 32(2):131-147.e7.

PMID: 38157856 PMC: 11145656. DOI: 10.1016/j.str.2023.11.015.

Advancement in COVID-19 detection using nanomaterial-based biosensors.

Truong P, Yin Y, Lee D, Ko S Exploration (Beijing). 2023; 3(1):20210232.

PMID: 37323622 PMC: 10191025. DOI: 10.1002/EXP.20210232.

Employing T-Cell Memory to Effectively Target SARS-CoV-2.

Tun Z, Htike N, Kyi-Tha-Thu C, Lee W Pathogens. 2023; 12(2).

PMID: 36839573 PMC: 9967959. DOI: 10.3390/pathogens12020301.

Immune Response to SARS-CoV-2 Vaccines.

Bellamkonda N, Lambe U, Sawant S, Nandi S, Chakraborty C, Shukla D Biomedicines. 2022; 10(7).

PMID: 35884770 PMC: 9312515. DOI: 10.3390/biomedicines10071464.

Antibodies to combat viral infections: development strategies and progress.

Pantaleo G, Correia B, Fenwick C, Joo V, Perez L Nat Rev Drug Discov. 2022; 21(9):676-696.

PMID: 35725925 PMC: 9207876. DOI: 10.1038/s41573-022-00495-3.

References

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

Kiley M, Regnery R, Johnson K . Ebola virus: identification of virion structural proteins. J Gen Virol. 1980; 49(2):333-41. DOI: 10.1099/0022-1317-49-2-333. View

Snijder E, Horzinek M . Toroviruses: replication, evolution and comparison with other members of the coronavirus-like superfamily. J Gen Virol. 1993; 74 ( Pt 11):2305-16. DOI: 10.1099/0022-1317-74-11-2305. View

Che X, Hao W, Qiu L, Pan Y, Liao Z, Xu H . [Antibody response of patients with severe acute respiratory syndrome (SARS) to nucleocapsid antigen of SARS-associated coronavirus]. Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(7):637-9. View

Atmar R, Glezen W, Greenberg S . Spectrum of clinical illness in hospitalized patients with "common cold" virus infections. Clin Infect Dis. 2000; 31(1):96-100. PMC: 7109925. DOI: 10.1086/313937. View

Kusters J, Jager E, Lenstra J, Koch G, Posthumus W, Meloen R . Analysis of an immunodominant region of infectious bronchitis virus. J Immunol. 1989; 143(8):2692-8. View

Benaroch P, Yilla M, Raposo G, Ito K, Miwa K, Geuze H . How MHC class II molecules reach the endocytic pathway. EMBO J. 1995; 14(1):37-49. PMC: 398050. DOI: 10.1002/j.1460-2075.1995.tb06973.x. View

Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo M . An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004; 10(8):871-5. PMC: 7095806. DOI: 10.1038/nm1080. View

Berry J, Jones S, Drebot M, Andonov A, Sabara M, Yuan X . Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods. 2004; 120(1):87-96. PMC: 7119589. DOI: 10.1016/j.jviromet.2004.04.009. View

10.

Lavi E, Schwartz T, Jin Y, Fu L . Nidovirus infections: experimental model systems of human neurologic diseases. J Neuropathol Exp Neurol. 1999; 58(12):1197-206. PMC: 7107479. DOI: 10.1097/00005072-199912000-00001. View

11.

Liang G, Chen Q, Xu J, Liu Y, Lim W, Peiris J . Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis. 2004; 10(10):1774-81. PMC: 3323270. DOI: 10.3201/eid1010.040445. View

12.

van der Hoek L, Pyrc K, Jebbink M, Vermeulen-Oost W, Berkhout R, Wolthers K . Identification of a new human coronavirus. Nat Med. 2004; 10(4):368-73. PMC: 7095789. DOI: 10.1038/nm1024. View

13.

Snijder E, Horzinek M, Spaan W . The coronaviruslike superfamily. Adv Exp Med Biol. 1993; 342:235-44. DOI: 10.1007/978-1-4615-2996-5_37. View

14.

Lai M . Coronavirus: organization, replication and expression of genome. Annu Rev Microbiol. 1990; 44:303-33. DOI: 10.1146/annurev.mi.44.100190.001511. View

15.

Hendley J, Fishburne H, Gwaltney Jr J . Coronavirus infections in working adults. Eight-year study with 229 E and OC 43. Am Rev Respir Dis. 1972; 105(5):805-11. DOI: 10.1164/arrd.1972.105.5.805. View

16.

Holmes K . SARS-associated coronavirus. N Engl J Med. 2003; 348(20):1948-51. DOI: 10.1056/NEJMp030078. View

17.

Harcourt B, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson K, Smith C . Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004; 78(24):13600-12. PMC: 533933. DOI: 10.1128/JVI.78.24.13600-13612.2004. View

18.

Ignjatovic J, Galli L . Structural proteins of avian infectious bronchitis virus: role in immunity and protection. Adv Exp Med Biol. 1993; 342:449-53. DOI: 10.1007/978-1-4615-2996-5_71. View

19.

Makela M, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimaki M . Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998; 36(2):539-42. PMC: 104573. DOI: 10.1128/JCM.36.2.539-542.1998. View

20.

Falsey A, Walsh E, Hayden F . Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis. 2002; 185(9):1338-41. PMC: 7109881. DOI: 10.1086/339881. View